Aims: To understand how coupled plasma filtration and adsorption (CPFA) could influence the time course of the advanced stages of sepsis, mean arterial pressure (MAP) and norepinephrine dosage. Methods: Patients with severe sepsis and septic shock with ≥2 organ failures not responding to volume resuscitation and vasopressor infusion were treated with CPFA within 8 h of admission to the intensive care unit. Results: Thirty-nine patients were treated (median age: 63 years, median SAPS II score: 45) and 28 survived advanced sepsis. In the latter, the median MAP increased and the norepinephrine dosage decreased significantly after CPFA, whereas in the nonsurvivors these values did not change significantly. The volume of treated plasma was significantly higher in survivors than nonsurvivors. Conclusion: These results suggest a possible existence of a dose-response effect for CPFA. Future studies are therefore recommended to evaluate the efficacy of this treatment and to determine its best timing and intensity.

Keywords:
Septic shock, Cytokines, Coupled plasma filtration and adsorption, Blood purification, Acute renal failure, Renal replacement therapies
1.
Honoré PM: Extracorporeal removal for sepsis: acting at the tissue level: the beginning of a new era for this treatment modality in septic shock. Crit Care Med 2004;32:896-897.
2.
Davies B, Davies J: Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis 2010;11:65-71.
3.
Tetta C, Bellomo R, Inguaggiato P, Wratten ML, Ronco C: Endotoxin and cytokine removal in sepsis. Ther Apher 2002;6:109-115.
4.
Ronco C, Bellomo R, Hormel P, et al: Effects of different doses in continuous veno-venous hemofiltration on outcomes of acute renal failure: a prospective, randomised trial. Lancet 2000;355:26-30.
5.
Oudemans-van Straaten HM, Bosman RJ, van der Spoel JI, et al: Outcome of critically ill patients treated with intermittent high volume haemofiltration: a prospective cohort analysis. Intensive Care Med 1999;25:814-821.
6.
Schiffl H, Lang SM, Fischer R: Daily haemodialysis and the outcome of acute renal failure. N Engl J Med 2002;346:305-310.
7.
Brause M, Neumann A, Schumacher T, et al: Effect of filtration volume of continuous venovenous haemofiltration in the treatment of patients with acute renal failure in intensive care units. Crit Care Med 2003;31:841-846.
8.
Vesconi S, Cruz DN, Fumagalli R, et al: Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Crit Care 2009;13:R57.
9.
Pannu N, Klarenbach S, Wiebe N, et al: Renal replacement therapy in patients with acute renal failure. JAMA 2008;299:793-805.
10.
Bellomo R, Tetta C, Ronco C: Coupled plasma filtration adsorption. Intensive Care Med 2003;29:1222-1228.
11.
Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-1256.
12.
Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34:17-60.
13.
Legall JR, Lemeshow S, Saulnier F: Development of a new scoring system, the SAPS II from a European-North American multicenter study. JAMA 1993;270:2957-2963.
14.
Vincent JL, Moreno R, Takala J, et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707-710.
15.
Rimmelé T, Kellum JA: Clinical review: blood purification for sepsis. Crit Care 2011;15:205-215.
16.
Venkataraman R, Subramanian S, Kellum JA: Clinical review: extracorporeal blood purification in severe sepsis. Crit Care 2003;7:139-145.
17.
Ronco C, Inguaggiato P, D'Intini V, et al: The role of extracorporeal therapies in sepsis. J Nephrol 2003;16(suppl 7):S34-S41.
18.
Honoré PM, Joannes-Boyau O, Boer W, Collin V: High-volume hemofiltration in sepsis and SIRS: current concepts and future directions. Blood Purif 2009;28:1-11.
19.
DiCarlo JV, Alexander SR: Hemofiltration for cytokine-driven illnesses: the mediator-delivery hypothesis. Int J Artif Organs 2005;28:777-786.
20.
Tetta C, Gianotti L, Cavaillon JM, et al: Coupled plasma filtration-adsorption in a rabbit model of endotoxic shock. Crit Care Med 2000;28:1526-1533.
21.
Sykora R, Chvojka J, Krouzecky A, et al: Coupled plasma filtration and adsorption in experimental peritonitis-induced septic shock. Shock 2009;31:473-480.
22.
Ronco C, Brendolan A, Lonneman NG, et al: A randomized cross-over study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002;30:1250-1255.
23.
Formica M, Olivieri C, Livigni S, et al: Hemodynamic response to coupled plasma filtration-adsorption in human septic shock. Intensive Care Med 2003;29:703-708.
24.
Lentini P, Cruz D, Nalesso F, et al: A pilot study comparing pulse high volume hemofiltration (pHVHF) and coupled plasma filtration adsorption (CPFA) in septic shock patients. G Ital Nefrol 2009;26:695-703.
25.
Prowle JR, Schneider A, Bellomo R: Clinical review: optimal dose of continuous renal replacement therapy in acute kidney injury. Crit Care 2011;15:207.
26.
Uchino S, Belomo R, Morimatsu H, et al: Continuous renal replacement therapy: a worldwide practice survey. Intensive Care Med 2007;33:1563-1570.
27.
Dahaba AA, El-Awadi GA, Rehak PH, List WF: Procalcitonin and proinflammatory cytokines clearance during continuous venovenous haemofiltration in septic patients. Anaesth Intensive Care 2002;30:269-274.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.